Blog
RSS FeedPosted by Michael Wonder on 25 Mar 2019
Eli Lilly sheds light on confidential drug pricing, discloses charges for popular diabetes medicine Humalog
25 March 2019 - Eli Lilly says the “net price” for insulin fell to $135 a patient a month in 2018 ...
Posted by Michael Wonder on 25 Mar 2019
Medicare for all would abolish private insurance. ‘There’s no precedent in American history.’
23 March 2019 - Unlike Obamacare, emerging plans would sweep away the private health insurance system. What would that mean for ...
Posted by Michael Wonder on 24 Mar 2019
As political scrutiny mounts, Eli Lilly divulges new insulin pricing data
24 March 2019 - Lilly says the price it was paid for popular insulin Humalog fell 8.1% from 2014 to 2018 ...
Posted by Michael Wonder on 24 Mar 2019
Drug prices on TV? They may be coming.
23 March 2019 - The Trump administration is moving ahead with its proposal to require drug companies to disclose the ...
Posted by Michael Wonder on 23 Mar 2019
Drug company protections are latest stumbling block for NAFTA rewrite
21 March 2019 - President Trump’s ability to get his revised North American Free Trade Agreement through Congress may hinge ...
Posted by Michael Wonder on 23 Mar 2019
Senate panel to hear from pharmacy middlemen on drug prices
21 March 2019 - The Senate Finance Committee said Thursday that it has secured commitments from executives of five major ...
Posted by Michael Wonder on 23 Mar 2019
FDA issues complete response letter for Zynquista (sotagliflozin)
22 March 2019 - The U.S. FDA issued a complete response letter regarding the New Drug Application for investigational Zynquista ...
Posted by Michael Wonder on 23 Mar 2019
FDA takes new steps to advance natural history studies for accelerating novel treatments for rare diseases
22 March 2019 - The U.S. FDA today issued the draft guidance, Rare Diseases: Natural History Studies for Drug Development. ...
Posted by Michael Wonder on 23 Mar 2019
Recro Pharma receives complete response letter from the FDA for intravenous meloxicam
22 March 2019 - Recro Pharma today announced it has received a second complete response letter from the U.S. FDA Office ...
Posted by Michael Wonder on 21 Mar 2019
Enzyvant's investigational Farber disease enzyme replacement therapy, RVT-801, receives FDA fast track and rare paediatric disease designations
21 March 2019 - Enzyvant today announced that the U.S. FDA has granted are paediatric disease and fast track designations for ...
Posted by Michael Wonder on 21 Mar 2019
Promoting biosimilars up to health plans, manufacturers, doctors, Gottlieb says
21 March 2019 - As he wraps up his final weeks as commissioner of the FDA, Scott Gottlieb, MD, talked about ...
Posted by Michael Wonder on 21 Mar 2019
Kentucky launches probe into drug overcharges by pharmacy benefit managers
22 March 2019 - Kentucky Attorney General Andy Beshear said on Thursday he had launched an investigation into allegations that ...
Posted by Michael Wonder on 21 Mar 2019
Institute for Clinical and Economic Review releases draft evidence report on esketamine for treatment-resistant depression
21 March 2019 - Public comment period now open until 17 April 2019; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 21 Mar 2019
Mystery solved: the pharma-backed group with a lot to say on Trump’s pitch to end drug rebates
20 March 2019 - RetireSafe, a Washington-based advocacy group with ties to the drug industry, appears to be behind a ...
Posted by Michael Wonder on 21 Mar 2019
FDA approves new device for treating moderate to severe chronic heart failure in patients
21 March 2019 - The U.S. FDA today approved the Optimizer Smart system for treating patients with chronic, moderate-to-severe heart failure ...